(J Am Heart Assoc. 2017;6:e004896 DOI: [10.1161/JAHA.116.004896](10.1161/JAHA.116.004896).)28476876

Introduction {#jah32145-sec-0004}
============

Dehydroepiandrosterone (DHEA) and its sulphated ester (DHEAS), working as multifunctional steroids[1](#jah32145-bib-0001){ref-type="ref"} are mainly produced in the adrenal cortex and converted to testosterone and estradiol in target tissues via androgen‐converting enzymes.[2](#jah32145-bib-0002){ref-type="ref"} DHEA is also synthesized in brain from 17OH pregnenolone and skin.[3](#jah32145-bib-0003){ref-type="ref"} It is suggested that DHEAS is a neuroactive steroid that would have a decisive role in the central nervous system, and some studies have established an association between DHEAS levels and degenerative disorders of the nervous system, including Addison\'s disease, Alzheimer\'s disease, depression, memory loss, and schizophrenia.[4](#jah32145-bib-0004){ref-type="ref"} The concentrations of DHEAS are sex related and vary during life.[5](#jah32145-bib-0005){ref-type="ref"} As both cortisol and DHEAS are synthesized within the adrenal cortex, and it is conceivable that their respective relative contributions to adrenal steroid output might define observed biological action. Furthermore, the cortisol to DHEAS ratio has been found to predict health outcomes better than the level of either hormone alone and in aging,[6](#jah32145-bib-0006){ref-type="ref"} Alzheimer\'s disease,[7](#jah32145-bib-0007){ref-type="ref"} metabolic syndrome,[8](#jah32145-bib-0008){ref-type="ref"}, [9](#jah32145-bib-0009){ref-type="ref"}, [10](#jah32145-bib-0010){ref-type="ref"} and all‐cause mortality (ACM).[10](#jah32145-bib-0010){ref-type="ref"}, [11](#jah32145-bib-0011){ref-type="ref"}, [12](#jah32145-bib-0012){ref-type="ref"}, [13](#jah32145-bib-0013){ref-type="ref"} By far, the strongest associations with the metabolic syndrome were observed in the cortisol/DHEAS ratio by Phillips et al.[8](#jah32145-bib-0008){ref-type="ref"} As DHEAS and cortisol have opposing effects on the innate immune system, while DHEAS enhances, cortisol suppresses, and the molar ratio of cortisol to DHEAS also increases with age, so it may be an important marker of glucocorticoid function.[14](#jah32145-bib-0014){ref-type="ref"}

It is not yet clear whether the physiological decline in DHEA represents a harmful deficiency resulting from aging and the occurrence of degenerative processes or an age‐related adaptation. Several studies have documented that DHEA and DHEAS might be implicated in a broad range of biological abnormalities including obesity, diabetes mellitus, osteoporosis, sexual dysfunction, cancer, and mental disorders, leading to speculation that a relative DHEAS deficiency may contribute to the development of common age‐related diseases or diminished longevity.[15](#jah32145-bib-0015){ref-type="ref"}, [16](#jah32145-bib-0016){ref-type="ref"}, [17](#jah32145-bib-0017){ref-type="ref"}, [18](#jah32145-bib-0018){ref-type="ref"}, [19](#jah32145-bib-0019){ref-type="ref"} Special interest in the role of DHEA dates back to the discovery of a relationship between a low serum concentration of DHEA and higher morbidity and mortality due to cardiovascular disease (CVD).[20](#jah32145-bib-0020){ref-type="ref"}, [21](#jah32145-bib-0021){ref-type="ref"}, [22](#jah32145-bib-0022){ref-type="ref"}, [23](#jah32145-bib-0023){ref-type="ref"} These findings were not confirmed by a later study[24](#jah32145-bib-0024){ref-type="ref"} and the issue remains controversial. Therefore, we performed a systematic review and meta‐analysis to clarify the impact of DHEAS on the prognosis of patients with CVD.

Methods {#jah32145-sec-0005}
=======

Search Strategy {#jah32145-sec-0006}
---------------

Literature searches were performed to identify all relevant and published studies focused on the prognostic value of DHEAS for patients with CVD. Two authors (T.‐T.W. and Y.C.) independently searched electronic databases (PubMed, Embase, Web of Science, CNKI, and WanFang) updated on September 5, 2016, using "DHEAS," "mortality," "CV event," and their corresponding index words as keywords.

Inclusion and Exclusion Criteria {#jah32145-sec-0007}
--------------------------------

Inclusion criteria were the following: (1) cohort studies that evaluated the prognostic value of DHEAS for patients with CVD; (2) studies with a follow‐up duration of more than 1 year; (3) studies that reported at least 1 of the following outcomes: ACM, cardiovascular events such as cardiovascular death, myocardial infarction, stroke, heart failure, and readmission; and (4) paper type: original prospective quantitative cohort study (ie, no review, commentary, case reports, editorial). Studies that met any of the following exclusion criteria were excluded: (1) animal or cell line studies; (2) duplicated publications; and (3) manuscripts published in languages other than English or Chinese. Disagreements were resolved by discussion and consensus.

Data Extraction {#jah32145-sec-0008}
---------------

Data extraction and quality assessment were performed independently by 2 authors (T.‐T.W. and Y.C.). The following data were extracted from eligible studies: names of the first authors, publication year, sources of participants, sample sizes, participants\' characteristics, follow‐up durations, end points with their corresponding hazard ratios (HRs), risk ratios, odds ratios, and 95% CIs, and the confounding factors adjusted for. The corresponding authors of the eligible studies were contacted for detailed information if the necessary data were not reported in the full text of the papers. If no valid data were achieved, then we will exclude this study. The Newcastle‐Ottawa Scale, with minor modifications, was used to assess the quality of the included studies. Any disagreements were resolved by discussion with a third author (Y.Z.) who was blinded to the previous results.

Statistical Analysis {#jah32145-sec-0009}
--------------------

Results reported as count data were presented for ACM, fatal cardiovascular events, and nonfatal cardiovascular events. We extracted the results of the lowest versus highest DHEAS concentrations and used the highest DHEAS category as the reference. If the study reported more than one estimate, only the result of the largest DHEAS difference was included. We transformed risk estimates by taking their natural logarithms and calculated the standard errors as follows: (Ln upper limit−Ln HR)/1.96. We weighted the natural logarithm of the risk estimates by generic inverse variance to account for the sample size and distribution of the included studies. We used Review Manager 5.1 (The Cochrane Collaboration, Oxford, United Kingdom) to analyze the collected data. The results of the included studies were pooled and meta‐analyses were carried out using fixed‐ or random‐effects models. Statistical heterogeneity between studies was assessed using the chi‐square test with significance set at *P*\<0.10, and heterogeneity was quantified using the *I* ^2^ statistic. *I* ^2^ values represent the proportion of total variation attributable to heterogeneity rather than chance whereby 0% is no observed heterogeneity and 100% is maximal heterogeneity.

Potential publication bias was evaluated by visual inspection of a funnel plot. A priori sensitivity analyses were defined to evaluate the stability of the pooled estimates and to examine changes in results after excluding specific studies. The subgroup analyses were preplanned for: length of follow‐up, study design, sample size, ethnicity, sex, and DHEAS categories as quartiles. The authors had full access to the data and take responsibility for its integrity. All authors read and agreed to the manuscript as written.

End Point Definition {#jah32145-sec-0010}
--------------------

The explored end points in this meta‐analysis are as follows: ACM; fatal cardiovascular events; nonfatal cardiovascular events; and fatal/nonfatal cardiovascular events.

Results {#jah32145-sec-0011}
=======

Summary of Eligible Studies {#jah32145-sec-0012}
---------------------------

Based on our search criteria, we identified 637 potentially relevant articles. By scanning the titles and abstracts we excluded 541 articles. A total of 71 studies were excluded for the following reasons: 33 lacked any of our requisite data and 27 were not related to CVD or CVD outcomes. Eleven were excluded based on study design. Overall, 25 cohort studies, with a total of 92 489 CVD patients, were included in our systematic review.[12](#jah32145-bib-0012){ref-type="ref"}, [13](#jah32145-bib-0013){ref-type="ref"}, [25](#jah32145-bib-0025){ref-type="ref"}, [26](#jah32145-bib-0026){ref-type="ref"}, [27](#jah32145-bib-0027){ref-type="ref"}, [28](#jah32145-bib-0028){ref-type="ref"}, [29](#jah32145-bib-0029){ref-type="ref"}, [30](#jah32145-bib-0030){ref-type="ref"}, [31](#jah32145-bib-0031){ref-type="ref"}, [32](#jah32145-bib-0032){ref-type="ref"}, [33](#jah32145-bib-0033){ref-type="ref"}, [34](#jah32145-bib-0034){ref-type="ref"}, [35](#jah32145-bib-0035){ref-type="ref"}, [36](#jah32145-bib-0036){ref-type="ref"}, [37](#jah32145-bib-0037){ref-type="ref"}, [38](#jah32145-bib-0038){ref-type="ref"}, [39](#jah32145-bib-0039){ref-type="ref"}, [40](#jah32145-bib-0040){ref-type="ref"}, [41](#jah32145-bib-0041){ref-type="ref"}, [42](#jah32145-bib-0042){ref-type="ref"}, [43](#jah32145-bib-0043){ref-type="ref"}, [44](#jah32145-bib-0044){ref-type="ref"}, [45](#jah32145-bib-0045){ref-type="ref"}, [46](#jah32145-bib-0046){ref-type="ref"}, [47](#jah32145-bib-0047){ref-type="ref"} For each of these studies, we extracted items including year of publication, name of the first author, country of origin of the research group, sample number of studies included, design used in the studies, quality evaluation of the studies, follow‐up time, confounder for adjustments, DHEAS concentration gradient, and end point. Results of the meta‐analysis on the main end point are expressed as HRs and 95% CIs.

A flowchart outlining our literature search is shown in Figure [1](#jah32145-fig-0001){ref-type="fig"}. A summary of the characteristics of the eligible studies is given in Table [1](#jah32145-tbl-0001){ref-type="table-wrap"}. Twenty‐one of the included studies were prospective cohort studies, whereas 4 were retrospective studies. For quality assessment, 25 studies were eligible and ranked according to their sum scores (Table [1](#jah32145-tbl-0001){ref-type="table-wrap"}), of which 21 studies were graded as "good" (scores \>6) and 4 as "moderate" (scores ≤6) quality.

![The flowchart of article inclusion. CVD indicates cardiovascular disease.](JAH3-6-e004896-g001){#jah32145-fig-0001}

###### 

Summary of Eligible Studies

  Author                                                         Year   Country          Ethnicity   Design          No. of Patients   Age, y           Men, %   Follow‐Up   Quality Evaluation
  -------------------------------------------------------------- ------ ---------------- ----------- --------------- ----------------- ---------------- -------- ----------- --------------------
  Blum et al[12](#jah32145-bib-0012){ref-type="ref"}             2013   United States    White       Prospective     231               71±14            59       1 y         6
  Phillips et al[13](#jah32145-bib-0013){ref-type="ref"}         2010   Vietnam          Asian       Retrospective   4255              38.3             100      15 y        8
  Maggio et al[25](#jah32145-bib-0025){ref-type="ref"}           2007   Italy            White       Retrospective   410               65--92           100      6 y         8
  Cappola et al[26](#jah32145-bib-0026){ref-type="ref"}          2006   United States    White       Prospective     539               77.6 (66--100)   0        5 y         7
  Page et al[27](#jah32145-bib-0027){ref-type="ref"}             2008   United States    White       Prospective     32 826            43--69           0        8--9 y      7
  Ohlsson et al[28](#jah32145-bib-0028){ref-type="ref"}          2010   Sweden           White       Prospective     2644              75.5±3.2         100      4.5 y       7
  Shufelt et al[29](#jah32145-bib-0029){ref-type="ref"}          2010   United States    White       Prospective     270               64±10            0        9 y         7
  Hsu et al[30](#jah32145-bib-0030){ref-type="ref"}              2012   Taiwan           Asian       Prospective     200               58.5±13.9        47       38.2 mo     7
  Trivedi et al[31](#jah32145-bib-0031){ref-type="ref"}          2001   United Kingdom   White       Prospective     963               65--76           100      6--10 y     7
  Trivedi et al[31](#jah32145-bib-0031){ref-type="ref"}          2001   United Kingdom   White       Prospective     1171              65--76           0        6--10 y     7
  Jansson et al[32](#jah32145-bib-0032){ref-type="ref"}          1998   Sweden           White       Prospective     123               ≤70              77       10.5 y      7
  Forti et al[33](#jah32145-bib-0033){ref-type="ref"}            2012   Italy            White       Prospective     920               73.7±6.6         45       8 y         8
  Jankowska et al[34](#jah32145-bib-0034){ref-type="ref"}        2010   Poland           White       Prospective     163               60±10            100      28 mo       8
  Jiménez et al[35](#jah32145-bib-0035){ref-type="ref"}          2013   United States    White       Prospective     32 826            43--69           0        10 y        6
  Sanders et al[36](#jah32145-bib-0036){ref-type="ref"}          2010   United States    White       Retrospective   989               85.2             36.5     9 y         7
  Feldman et al[37](#jah32145-bib-0037){ref-type="ref"}          2001   United States    White       Prospective     1167              40--70           100      8.9 y       7
  Ponholzer et al[38](#jah32145-bib-0038){ref-type="ref"}        2009   Vienna           White       Prospective     247               75.8             100      5 y         7
  Glei et al[39](#jah32145-bib-0039){ref-type="ref"}             2006   Taiwan           Asian       Prospective     963               54--91           57.9     3 y         8
  Fukai et al[40](#jah32145-bib-0040){ref-type="ref"}            2011   Japan            Asian       Prospective     97                83±7             0        45 mo       8
  Arnlöv et al[41](#jah32145-bib-0041){ref-type="ref"}           2006   United States    White       Prospective     1928              55±12            100      10 y        7
  Tivesten et al[42](#jah32145-bib-0042){ref-type="ref"}         2014   Sweden           White       Prospective     2416              75.4±3.2         100      5 y         8
  Güder et al[43](#jah32145-bib-0043){ref-type="ref"}            2009   German           White       Prospective     191               64.4             100      859 d       7
  Barrett‐Connor et al[44](#jah32145-bib-0044){ref-type="ref"}   1995   United States    White       Prospective     1971              60.4±12.8        52.2     19 y        6
  LaCroix et al[45](#jah32145-bib-0045){ref-type="ref"}          1992   Japan            Asian       Prospective     3775              45--68           100      18 y        6
  Haring et al[46](#jah32145-bib-0046){ref-type="ref"}           2013   German           White       Prospective     254               75.5             100      10 y        7
  Cappola et al[47](#jah32145-bib-0047){ref-type="ref"}          2009   United States    White       Retrospective   950               72.9             49       8 y         7

Main Findings of Eligible Studies {#jah32145-sec-0013}
---------------------------------

Table [2](#jah32145-tbl-0002){ref-type="table-wrap"} shows the main findings of all eligible studies. Seven studies used DHEAS concentrations as a continuous variable with different variability (per SD in DHEAS, per quartile increment in DHEAS, per 10‐, 50‐, and 100‐μg/dL difference in DHEAS), investigating the relationship between DHEAS and ACM and fatal and nonfatal cardiovascular events, respectively.[41](#jah32145-bib-0041){ref-type="ref"}, [42](#jah32145-bib-0042){ref-type="ref"}, [43](#jah32145-bib-0043){ref-type="ref"}, [44](#jah32145-bib-0044){ref-type="ref"}, [45](#jah32145-bib-0045){ref-type="ref"}, [46](#jah32145-bib-0046){ref-type="ref"}, [47](#jah32145-bib-0047){ref-type="ref"} Finally, in 18 studies, the authors used the lowest versus highest or dichotomous cutoff values of DHEAS concentrations as categories and used the highest DHEAS category as the reference, and calculated the data risk estimates (HRs/odds ratios), regression coefficients, and 95% CIs. Eleven studies investigated the relationship between DHEAS and ACM, 6 investigated fatal cardiovascular events, and 7 investigated nonfatal cardiovascular events. The confounding factors adjusted for among the eligible studies varied, including age, smoking, systolic and diastolic blood pressure, hypertension, high‐density lipoprotein cholesterol, total cholesterol, diabetes mellitus, BMI, high serum C‐reactive protein, Apolipoprotein B to Apolipoprotein A1 ratio, and low testosterone.

###### 

Main Findings of the Eligible Studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                         Year   Baseline Diseases              Outcome                            Adjustments                                                                                                                                                                                                                                                                                                                                                                                                                                     HR                   Normalized DHEAS                Categories
  -------------------------------------------------------------- ------ ------------------------------ ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------- -----------------------------------
  Blum et al[12](#jah32145-bib-0012){ref-type="ref"}             2013   Acute ischemic stroke          Mortality\                         Age, sex, Charlson index                                                                                                                                                                                                                                                                                                                                                                                                                        1.6 (0.85--3.8)\     91.86 μg/dL (49.76--141.62)     Dichotomous cutoff values\
                                                                                                       Poor functional outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                            1.23 (1.01--1.49)                                    Low vs high

  Phillips et al[13](#jah32145-bib-0013){ref-type="ref"}         2010   ···                            ACM\                               Age and other covariates/fully adjusted/age and fully adjusted                                                                                                                                                                                                                                                                                                                                                                                  0.55 (0.43--0.71)\   239.8±99.86 μg/dL               DHEAS logged\
                                                                                                       CM\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                0.4 (0.23--0.7)\                                     HR
                                                                                                       OM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.45 (0.3--0.67)                                     

  Maggio et al[25](#jah32145-bib-0025){ref-type="ref"}           2007   ···                            ACM                                Age, BMI, cancer, log (interleukin 6), education, cognitive function, depression, physical activity, caloric and alcohol intake, smoking, CHD (including angina and MI), CHF, stroke, diabetes mellitus, hypertension, Parkinson disease, peripheral artery disease, asthma, cancer, and COPD                                                                                                                                                   1.38 (0.84--2.26)    50 μg/dL                        Dichotomous cutoff values\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Low vs high

  Cappola et al[26](#jah32145-bib-0026){ref-type="ref"}          2006   Disabled women                 Mortality                          Age, education, race, smoking status, BMI, estrogen use, corticosteroid use, chronic conditions including CHD, CHF, peripheral artery disease, hip fracture, osteoarthritis, rheumatoid arthritis, DM, cancer, stroke, and COPD                                                                                                                                                                                                                 2.05 (1.27--3.32)    ≤21.6 μg/dL\                    Q1 vs Q3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \>21.6, ≤39.7\                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \>39.7, ≤67.9\                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \>67.9                          

  Page et al[27](#jah32145-bib-0027){ref-type="ref"}             2008   Postmenopausal women           MI                                 Age at blood draw, time of blood collection, fasting status at blood collection, menopausal status, parents\' history of MI, current postmenopausal hormone use, history of DM, history of hypertension, history of hypercholesterolemia, aspirin use, mean alcohol intake, BMI, physical activity in metabolic equivalent hours                                                                                                                1.58 (1.09--2.3)     27.14 μg/dL\                    Q1 vs Q4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               27.14--42.49\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               42.50--64.08\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ≥64.09                          

  Ohlsson et al[28](#jah32145-bib-0028){ref-type="ref"}          2010   ···                            ACM\                               Age, current smoking, BMI, DM, hypertension, Apolipoprotein B to Apolipoprotein A1 ratio, low testosterone, low estradiol                                                                                                                                                                                                                                                                                                                       1.49 (1.17--1.89)\   3.7 μg/dL                       Dichotomous cutoff values\
                                                                                                       CM\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1.61 (1.10--2.38)\                                   Low vs high
                                                                                                       IHD mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1.66 (1.01--2.72)                                    

  Shufelt et al[29](#jah32145-bib-0029){ref-type="ref"}          2010   Postmenopausal women with MI   ACM\                               Age, ethnicity, established CVD risk factors                                                                                                                                                                                                                                                                                                                                                                                                    2.26 (1.08--4.75)\   24.7 μg/dL                      Dichotomous cutoff values\
                                                                                                       CM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2.43 (1.06--5.56)                                    Low vs high

  Hsu et al[30](#jah32145-bib-0030){ref-type="ref"}              2012   CKD hemodialysis men           ACM\                               Age, DM, COPD, cardiothoracic ratio, hs‐CRP, dialysis duration, albumin creatinine                                                                                                                                                                                                                                                                                                                                                              2.93 (1.09--7.89)\   7.9 μg/dL                       Dichotomous cutoff values\
                                                                                                       CM\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                3.81 (0.91--15.9)\                                   Low vs high
                                                                                                       OM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2.18 (0.52--9.05)                                    

  Trivedi et al[31](#jah32145-bib-0031){ref-type="ref"}          2001   ···                            ACM\                               Age, BP, BMI, cholesterol, current smokers, steroid use, hormone replacement therapy use, history of CVD or cancer                                                                                                                                                                                                                                                                                                                              Men\                 61.24 μg/dL\                    Q1 vs Q4
                                                                                                       CM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1.37 (0.91--2.08)\   61.24--95.69\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1.79 (1.03--3.13)    95.70--145.45\                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \>145.45                        

                                                                 2001   ···                            ACM\                               Age, BP, BMI, cholesterol, current smokers, steroid use, hormone replacement therapy use, history of CVD or cancer                                                                                                                                                                                                                                                                                                                              Women\               38.28 μg/dL\                    Q1 vs Q4
                                                                                                       CM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.87 (0.53--1.45)\   38.28--57.41\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          0.84 (0.41--1.72)    57.42--80.03\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \>80.04                         

  Jansson et al[32](#jah32145-bib-0032){ref-type="ref"}          1998   Acute MI                       CM                                 Univariate                                                                                                                                                                                                                                                                                                                                                                                                                                      1.79 (0.84--3.70)    176.07 μg/dL (145.45--202.87)   Q1 vs Q4

  Forti et al[33](#jah32145-bib-0033){ref-type="ref"}            2012   ···                            ACM                                Age and baseline presence of smoking, BMI, IHD, disability, frailty (not included in the model for women stratified by frailty status), preexisting major diseases (not included in the model for women stratified by preexisting major diseases), Geriatric Depression Scale, Mini‐Mental State Examination, and hs‐CRP                                                                                                                        1.45 (0.98--2.17)    ≤57.42 μg/dL\                   Q1 vs Q4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               57.43--86.51\                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               86.52--135.88\                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ≥135.89                         

  Jankowska et al[34](#jah32145-bib-0034){ref-type="ref"}        2010   CHF                            CM and unplanned hospitalization   Beck Depression Inventory, serum total testosterone, LVEF, BMI, CHF etiology, CAD vs non‐CAD, plasma NT‐proBNP, eGFR, NYHA class, hemoglobin, age, DM\                                                                                                                                                                                                                                                                                          1.95 (1.23--3.10)    6.48 μg/dL (3.60--13.15)        Dichotomous cutoff values\
                                                                                                                                          Variables selected based on stepwise approach                                                                                                                                                                                                                                                                                                                                                                                                                                                        Low vs high

  Jiménez et al[35](#jah32145-bib-0035){ref-type="ref"}          2013   ···                            Ischemic stroke                    Age, ancestry, menopausal status, hormone use, smoking, date of blood collection, BMI, aspirin use, alcohol intake, physical activity, Alternative Healthy Eating Index, history of DM, hypertension, and CHD, or revascularization, glycated hemoglobin, and total/HDL‐C                                                                                                                                                                       1.44 (0.93--2.23)    \<42 μg/dL\                     Q1 vs Q4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               42--65.2\                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               65.6--101\                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \>101.5                         

  Sanders et al[36](#jah32145-bib-0036){ref-type="ref"}          2010   ···                            CVD                                All factors in the full model plus mean age, BMI, and cholesterol. CVD or CHD and CBD were added separately                                                                                                                                                                                                                                                                                                                                     1.46 (1.03--2.05)    55.5 μg/dL\                     Dichotomous cutoff values
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ±41.4                           

  Feldman et al[37](#jah32145-bib-0037){ref-type="ref"}          2001   ···                            IHD                                Age, race, married, education, employed, serum cholesterol, low HDL‐C, obesity, DM, hypertension, cigarette smoking, passive smoking, home and work moderate to vigorous physical activity, and alcohol consumption                                                                                                                                                                                                                             1.97 (1.12--3.48)    2.7--15.9 μg/dL\                Q1 vs Q4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               16.0--23.4\                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               23.5--33.0\                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               33.1--123                       

  Ponholzer et al[38](#jah32145-bib-0038){ref-type="ref"}        2009   ···                            CVD                                No mention                                                                                                                                                                                                                                                                                                                                                                                                                                      1.85 (1.05--3.23)    50 μg/dL                        Dichotomous cutoff values

  Glei et al[39](#jah32145-bib-0039){ref-type="ref"}             2006   ···                            Mortality                          Various indicators of health status in 2000                                                                                                                                                                                                                                                                                                                                                                                                     1.41 (1.31--1.52)    54.5 μg/dL                      Dichotomous cutoff values

  Fukai et al[40](#jah32145-bib-0040){ref-type="ref"}            2011   ···                            ACM                                Age, nutritional parameters, functional parameters, and prevalent disease                                                                                                                                                                                                                                                                                                                                                                       4.42 (1.51--12.9)    43 μg/dL                        Dichotomous cutoff values

  Arnlöv et al[41](#jah32145-bib-0041){ref-type="ref"}           2006   ···                            CVD                                Age, smoking, systolic and diastolic BP, hypertension treatment, total cholesterol--HDL‐C ratio, DM, and BMI                                                                                                                                                                                                                                                                                                                                    1.02 (0.90--1.15)    24.50±19.14 μg/dL               Per 1 SD increase in log DHEAS

  Tivesten et al[42](#jah32145-bib-0042){ref-type="ref"}         2014   ···                            CVD\                               Age, Osteoporotic Fractures in Men study site, morning sample, current smoking, BMI, DM, hypertension, Apolipoprotein B and Apolipoprotein A1. Log10‐transformed values of DHEA, DHEAS, BMI, and hs‐CRP                                                                                                                                                                                                                                         0.87 (0.78--0.98)\   7.1±4.6 μg/dL                   Per SD increase
                                                                                                       CBD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                0.9 (0.79--1.02)                                     

  Güder et al[43](#jah32145-bib-0043){ref-type="ref"}            2009   Heart failure                  ACM                                Age, NYHA class, free testosterone: renal function, atrial fibrillation, systolic BP, C‐reactive protein, NT‐proBNP, intake of diuretics, cortisol; for DHEAS: renal function, atrial fibrillation, total cholesterol, NT‐proBNP, intake of diuretics, intake of β‐blockers; for sex hormone--binding globulin: renal function, atrial fibrillation, NT‐proBNP, intake of angiotensin‐converting enzyme inhibitor, intake of statin, cortisol   0.97 (0.91--1.03)    73 (36--131) μg/dL              DHEAS per 10 μg/dL

  Barrett‐Connor et al[44](#jah32145-bib-0044){ref-type="ref"}   1995   ···                            ACM\                               Age, BP, smoking, total cholesterol, BMI, fasting plasma glucose, and replacement estrogen                                                                                                                                                                                                                                                                                                                                                      0.93 (0.9--0.95)\    154 μg/dL                       A 50‐μg/dL decrease in risk ratio
                                                                                                       CM\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                0.94 (0.84--1.03)\                                   
                                                                                                       IHD mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0.96 (0.85--1.05)                                    

  LaCroix et al[45](#jah32145-bib-0045){ref-type="ref"}          1992   ···                            MI                                 Systolic BP, serum cholesterol, subscapular skinfold, serum glucose, diabetes mellitus medication, alcohol, physical activity index                                                                                                                                                                                                                                                                                                             0.72 (0.45--1.14)    5--65 μg/dL\                    100‐μg/dL difference
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               66--92\                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               93--114\                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               115--140\                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               141--277                        

  Haring et al[46](#jah32145-bib-0046){ref-type="ref"}           2013   ···                            ACM\                               Age, BMI, smoking, total cholesterol, HDL‐C, type 2 DM, systolic BP, and antihypertensive medication                                                                                                                                                                                                                                                                                                                                            1.18 (0.96--145)\    99.52 (70.81--46.22) μg/dL      Variability (per Q increment)
                                                                                                       CVD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1.00 (0.82--1.22)                                    

  Cappola et al[47](#jah32145-bib-0047){ref-type="ref"}          2009   ···                            Mortality                          Age, sex, race, CVD, pulmonary disease, DM, cancer, depression                                                                                                                                                                                                                                                                                                                                                                                  1.89 (1.47--2.43)    0.82 (0.51--1.2) μg/dL          Variability (per SD)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACM indicates all‐cause mortality; BP, blood pressure; CAD, coronary artery disease; CBD, cerebrovascular disease; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; CM, cardiovascular mortality; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; HR, hazard ratio; hs‐CRP, high serum C‐reactive protein; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; OM, other mortality; Q, quartile.

DHEAS and Outcomes {#jah32145-sec-0014}
------------------

### DHEAS and ACM {#jah32145-sec-0015}

There were 11 studies that reported positive associations between low DHEAS concentrations and ACM. Meta‐analysis results showed that CVD with low DHEAS was associated with a 47% higher risk of future mortality events (HR, 1.47; 95% CI, 1.38--1.56 \[*P*\<0.00001\] (Figure [2](#jah32145-fig-0002){ref-type="fig"}).

![The relationship between dehydroepiandrosterone sulfate and all‐cause mortality.](JAH3-6-e004896-g002){#jah32145-fig-0002}

### DHEAS and fatal/nonfatal cardiovascular events {#jah32145-sec-0016}

Six studies investigated deficient DHEAS level and fatal cardiovascular events,[13](#jah32145-bib-0013){ref-type="ref"}, [28](#jah32145-bib-0028){ref-type="ref"}, [29](#jah32145-bib-0029){ref-type="ref"}, [30](#jah32145-bib-0030){ref-type="ref"}, [31](#jah32145-bib-0031){ref-type="ref"}, [32](#jah32145-bib-0032){ref-type="ref"} 7 studies[12](#jah32145-bib-0012){ref-type="ref"}, [27](#jah32145-bib-0027){ref-type="ref"}, [28](#jah32145-bib-0028){ref-type="ref"}, [35](#jah32145-bib-0035){ref-type="ref"}, [36](#jah32145-bib-0036){ref-type="ref"}, [37](#jah32145-bib-0037){ref-type="ref"}, [38](#jah32145-bib-0038){ref-type="ref"} investigated low DHEAS and nonfatal cardiovascular events, and 1 study[34](#jah32145-bib-0034){ref-type="ref"} reported DHEAS with fatal/nonfatal cardiovascular events separately. In the meta‐analysis, the pooled estimates for the lowest compared with the highest category of baseline DHEAS indicated a significant increased risk for fatal cardiovascular events without heterogeneity (*I* ^2^=0%): pooled risk ratio, 1.58 (95% CI, 1.30--1.91; *P*\<0.00001 \[Figure [3](#jah32145-fig-0003){ref-type="fig"}\]).

![The relationship between dehydroepiandrosterone sulfate and fatal cardiovascular events.](JAH3-6-e004896-g003){#jah32145-fig-0003}

The pooled estimate for nonfatal cardiovascular events resulted in a slightly higher association: risk ratio, 1.42 (95% CI, 1.24--1.62; *P*\<0.00001 \[Figure [4](#jah32145-fig-0004){ref-type="fig"}\]), with no heterogeneity (*I* ^2^=0%). The HR for the fatal/nonfatal cardiovascular events resulted in a higher association: risk ratio 1.95 (95% CI, 1.23--3.10; *P*=0.005).

![The relationship between dehydroepiandrosterone sulfate and nonfatal cardiovascular events.](JAH3-6-e004896-g004){#jah32145-fig-0004}

Subgroup Analysis {#jah32145-sec-0017}
-----------------

To explore possible sources of heterogeneity among the eligible studies, subgroup analysis was performed. As shown in Tables [3](#jah32145-tbl-0003){ref-type="table-wrap"}, [4](#jah32145-tbl-0004){ref-type="table-wrap"} through [5](#jah32145-tbl-0005){ref-type="table-wrap"}, different set of variables seemed to have no apparent effect on pooled HRs. At the same time, we performed subgroup analysis according to sex (see Figure [5](#jah32145-fig-0005){ref-type="fig"}).

###### 

Subgroup Analysis (ACM)

  Subgroup                                     Design        No. of Studies   Sample Sizes   Heterogeneity   Meta‐Analysis                
  -------------------------------------------- ------------- ---------------- -------------- --------------- --------------- ------------ ------------
  Study design                                 Prospective   9                7998           36              \<0.0001        1.43         1.34--1.53
  Retrospective                                2             4665             0              \<0.0001        1.70            1.46--1.98   
  Sample size                                  \<1000        8                3630           21              \<0.0001        1.44         1.34--1.54
  ≥1000                                        3             9033             72             0.02            1.43            1.07--1.91   
  Follow‐up                                    \<4 y         4                1491           54              0.01            1.95         1.17--3.25
  ≥4 y                                         7             11 172           0              \<0.0001        1.58            1.42--1.76   
  Ethnicity                                    Asian         4                5515           73              \<0.0001        1.69         1.32--2.16
  Non‐Asian                                    7             7148             9              \<0.0001        1.46            1.26--1.69   
  Studies with DHEAS categories as quartiles   Yes           4                7848           0               0.03            1.39         1.12--1.73
  No                                           7             4815             0              \<0.0001        1.43            1.34--1.54   

ACM indicates all‐cause mortality; DHEAS: dehydroepiandrosterone sulfate; HR, hazard ratio.

###### 

Subgroup Analysis (Fatal Cardiovascular Event)

  Subgroup                                     Design   No. of Studies   Sample Sizes   Heterogeneity   Meta‐Analysis                
  -------------------------------------------- -------- ---------------- -------------- --------------- --------------- ------------ ------------
  Sample size                                  \<1000   4                1556           0               0.0003          2.01         1.38--2.94
  ≥1000                                        3        8070             22             0.001           1.45            1.16--1.81   
  Ethnicity                                    Asian    2                4455           36              0.003           1.55         1.16--2.08
  Non‐Asian                                    4        5171             7              \<0.0003        1.60            1.24--2.06   
  Studies with DHEAS categories as quartiles   Yes      3                2257           0               0.05            1.45         0.99--2.12
  No                                           4        7369             0              \<0.0001        1.62            1.30--2.03   

DHEAS indicates dehydroepiandrosterone sulfate; HR, hazard ratio.

###### 

Subgroup Analysis (Nonfatal Cardiovascular Event)

  Subgroup                                     Design   No. of Studies   Sample Sizes   Heterogeneity   Meta‐Analysis                
  -------------------------------------------- -------- ---------------- -------------- --------------- --------------- ------------ ------------
  Sample size                                  \<1000   3                1467           8               0.0009          1.32         1.12--1.56
  ≥1000                                        4        69 463           10             \<0.0001        1.61            1.29--2.02   
  Studies with DHEAS categories as quartiles   Yes      3                66 819         0               0.0003          1.60         1.24--2.06
  No                                           4        4111             0              0.0001          1.35            1.16--1.58   

DHEAS indicates dehydroepiandrosterone sulfate; HR, hazard ratio.

![Subgroup analysis of the relationship between dehydroepiandrosterone sulfate and prognosis of cardiovascular (CV) disease. ACM indicates all‐cause mortality.](JAH3-6-e004896-g005){#jah32145-fig-0005}

Publication Bias {#jah32145-sec-0018}
----------------

The funnel plot (Figure [6](#jah32145-fig-0006){ref-type="fig"}) for studies of DHEAS and ACM and fatal and nonfatal cardiovascular events shows reasonable symmetry at the top of the funnel plot and slight asymmetry at the bottom, suggesting some evidence of publication bias for small studies.

![Funnel plots for publication bias test. A, All‐cause mortality; (B) fatal cardiovascular events; (C) nonfatal cardiovascular events.](JAH3-6-e004896-g006){#jah32145-fig-0006}

Discussion {#jah32145-sec-0019}
==========

In this meta‐analysis, we found that CVD patients with lower DHEAS levels may have poorer prognosis than those with higher DHEAS levels. To the best of our knowledge, this is the first systematic review and meta‐analysis to clarify the relationship between DHEAS and CVD outcomes.

Our meta‐analysis included all English‐language and Chinese‐language published studies up until September 5, 2016, that compared CVD outcomes in patients with lower or higher concentration of DHEAS. Twenty‐five published studies were selected according to specified inclusion criteria, for a total of 92 489 patients. Of note, a lower concentration of DHEAS was associated with a significantly increased risk of overall mortality when all studies were considered (risk ratio, 1.47; 95% CI, 1.38--1.56).

Sex hormones play a pivotal role in regulating body composition both in men and women. DHEAS as their precursor has been shown to have many biological effects, and the clinical significance of DHEA and DHEAS in CVD remains uncertain. Epidemiological studies demonstrate that the association between low DHEAS and all‐cause disease or CVD mortality is conflicting. Most of the studies in men show a negative relationship between DHEAS level and mortality and CVD mobility.[20](#jah32145-bib-0020){ref-type="ref"}, [30](#jah32145-bib-0030){ref-type="ref"}, [31](#jah32145-bib-0031){ref-type="ref"}, [36](#jah32145-bib-0036){ref-type="ref"}, [39](#jah32145-bib-0039){ref-type="ref"}, [47](#jah32145-bib-0047){ref-type="ref"}, [48](#jah32145-bib-0048){ref-type="ref"} Similar conclusions in postmenopausal women with low DHEAS levels have been reported and are associated with higher cardiovascular mortality.[27](#jah32145-bib-0027){ref-type="ref"}, [29](#jah32145-bib-0029){ref-type="ref"} Conversely, no association was observed between DHEAS and mortality in several studies.[49](#jah32145-bib-0049){ref-type="ref"}, [50](#jah32145-bib-0050){ref-type="ref"}, [51](#jah32145-bib-0051){ref-type="ref"} Our meta‐analysis including 92 489 patients clarified the relationship between DHEAS and CVD prognosis, which indicated the adrenal androgen DHEA and its sulfate form DHEAS, may be markers of the aging process and potential longevity.[52](#jah32145-bib-0052){ref-type="ref"}

Much evidence has indicated that obesity, type 2 diabetes mellitus, and the metabolic syndrome in men are all characterized by a hypogonadotropic hypogonadism, strictly related to body fat mass.[53](#jah32145-bib-0053){ref-type="ref"}, [54](#jah32145-bib-0054){ref-type="ref"}, [55](#jah32145-bib-0055){ref-type="ref"}, [56](#jah32145-bib-0056){ref-type="ref"} Corona et al[57](#jah32145-bib-0057){ref-type="ref"} reported that DHEA supplementation was associated with a reduction of fat mass and a trend toward an increase in lean mass. Although these effects were small and can be accounted for by adjustment for DHEA‐derived metabolites, it provides a new train of thought to prevent the occurrence of CVD and reduce the long‐term risk of death.

The mechanisms of the effect of DHEA and DHEAS on health outcomes remain unclear. Although DHEAS does not directly interact with the glucocorticoid receptor, research suggests that it may act as a functional antagonist to the effects of glucocorticoids.[58](#jah32145-bib-0058){ref-type="ref"}, [59](#jah32145-bib-0059){ref-type="ref"}, [60](#jah32145-bib-0060){ref-type="ref"} This counterbalancing action might explain the relationship between DHEAS level and health outcomes known to be affected by chronically elevated cortisol levels, such as heart disease, diabetes mellitus, and cognitive impairment.[61](#jah32145-bib-0061){ref-type="ref"}, [62](#jah32145-bib-0062){ref-type="ref"} A direct role for DHEA in opposing atherosclerosis is suggested by its ability to facilitate fibrinolysis,[63](#jah32145-bib-0063){ref-type="ref"}, [64](#jah32145-bib-0064){ref-type="ref"} inhibit platelet aggregation, and retard cell proliferation.[65](#jah32145-bib-0065){ref-type="ref"} Previous pathological research elucidated that the zona reticularis, which is responsible for DHEA production, is highly susceptibility to vascular damage.[66](#jah32145-bib-0066){ref-type="ref"} Given these findings, DHEAS might reflect underlying vascular disease manifesting as endocrine dysfunction.

Study Limitations {#jah32145-sec-0020}
-----------------

Limitations of the present meta‐analysis are essentially associated with the overall weakness of the studies reviewed, including the small size of the studies, the low statistical power, the often unreliable analytical methods for steroid detection, the different evaluation of confounding factors in the different studies such as sex, age, smoking, diabetes mellitus, metabolic syndrome, hypertension, obesity, dyslipidemia, and thyroid disease; the variation of aldosterone values; the treatments with corticosteroids or hypertension or menopause in women; the use of aldosteronereceptor blockers, different kinds of diuretics and other drugs that affect DHEAS level. At last, the differences in the clinical end points or populations analyzed. There is still a lack of basic understanding of the biological effects of DHEA and DHEAS and further data in men and in women from prospective studies including better assessment of covariates, and randomized trials are urgently needed.

Conclusions {#jah32145-sec-0021}
===========

The results of the present meta‐analysis indicate that DHEAS is a poor prognostic marker for patients with CVD. Further studies are needed to uncover the potential mechanisms between low DHEAS level and poor prognosis in CVD patients.
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